Loading...

Ecofibre

ASX:EOF
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EOF
ASX
A$668M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Ecofibre Limited, together with its subsidiaries, produces and sells hemp products in the United States and Australia. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • Ecofibre has significant price volatility in the past 3 months.
EOF Share Price and Events
7 Day Returns
8%
ASX:EOF
3.3%
AU Pharmaceuticals
4%
AU Market
1 Year Returns
-
ASX:EOF
-27.5%
AU Pharmaceuticals
5.2%
AU Market
EOF Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ecofibre (EOF) 8% -2.7% - - - -
AU Pharmaceuticals 3.3% -5.6% -3.5% -27.5% -38.2% -25.9%
AU Market 4% 3.5% 5.9% 5.2% 21.7% 9.6%
1 Year Return vs Industry and Market
  • No trading data on EOF.
  • No trading data on EOF.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Ecofibre undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Ecofibre. This is due to cash flow or dividend data being unavailable. The share price is A$2.16.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ecofibre's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ecofibre's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:EOF PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.08
ASX:EOF Share Price ** ASX (2019-05-21) in AUD A$2.16
Australia Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 20.55x
Australia Market PE Ratio Median Figure of 542 Publicly-Listed Companies 15.99x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ecofibre.

ASX:EOF PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:EOF Share Price ÷ EPS (both in AUD)

= 2.16 ÷ -0.08

-27.97x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ecofibre is loss making, we can't compare its value to the AU Pharmaceuticals industry average.
  • Ecofibre is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Ecofibre's expected growth come at a high price?
Raw Data
ASX:EOF PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -27.97x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Pharmaceuticals Industry PEG Ratio Median Figure of 118 Publicly-Listed Pharmaceuticals Companies 1.53x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.4x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ecofibre, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ecofibre's assets?
Raw Data
ASX:EOF PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.12
ASX:EOF Share Price * ASX (2019-05-21) in AUD A$2.16
Australia Pharmaceuticals Industry PB Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 3.35x
Australia Market PB Ratio Median Figure of 1,678 Publicly-Listed Companies 1.63x
ASX:EOF PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:EOF Share Price ÷ Book Value per Share (both in AUD)

= 2.16 ÷ 0.12

17.62x

* Primary Listing of Ecofibre.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ecofibre is overvalued based on assets compared to the AU Pharmaceuticals industry average.
X
Value checks
We assess Ecofibre's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Ecofibre has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Ecofibre expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ecofibre has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
51.8%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ecofibre expected to grow at an attractive rate?
  • Unable to compare Ecofibre's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Ecofibre's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Ecofibre's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:EOF Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 51.8%
Australia Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 32.5%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.9%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:EOF Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:EOF Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 18 -3 -7
2018-09-30 12 -5 -8
2018-06-30 6 -7 -9
2017-06-30 1 -7 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Ecofibre is high growth as no earnings estimate data is available.
  • Unable to determine if Ecofibre is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:EOF Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Ecofibre Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:EOF Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.08
2018-09-30 -0.09
2018-06-30 -0.11
2017-06-30 -0.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ecofibre will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Ecofibre's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Ecofibre's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Ecofibre's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ecofibre has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Ecofibre performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ecofibre's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ecofibre does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Ecofibre's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ecofibre's 1-year growth to the Global Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Ecofibre's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ecofibre Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:EOF Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 17.81 -6.72 15.94
2018-09-30 11.78 -7.67 13.44
2018-06-30 5.75 -8.63 10.93
2017-06-30 0.58 -8.65 4.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ecofibre has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ecofibre has efficiently used its assets last year compared to the AU Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ecofibre improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ecofibre's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ecofibre has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Ecofibre's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ecofibre's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ecofibre is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ecofibre's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ecofibre's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ecofibre Company Filings, last reported 4 months ago.

ASX:EOF Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 10.66 3.81 5.93
2018-09-30 10.66 3.81 5.93
2018-06-30 1.56 6.07 2.76
2017-06-30 -0.79 5.90 2.45
  • Ecofibre's level of debt (35.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Ecofibre's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ecofibre has less than a year of cash runway based on current free cash flow.
  • Ecofibre has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4% each year.
X
Financial health checks
We assess Ecofibre's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ecofibre has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Ecofibre's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ecofibre dividends.
If you bought A$2,000 of Ecofibre shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ecofibre's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ecofibre's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:EOF Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 144 Stocks 3%
Australia Market Average Dividend Yield Market Cap Weighted Average of 414 Stocks 4.2%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.6%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ecofibre has not reported any payouts.
  • Unable to verify if Ecofibre's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ecofibre's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ecofibre has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Ecofibre's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ecofibre afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ecofibre has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Ecofibre's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Eric Wang
TENURE AS CEO 1.4 years
CEO Bio

Mr. Eric Wang has been Chief Executive Officer and Managing Director of Ecofibre Limited since December 2017 and has been its Director since December 2015. Mr. Wang has over twenty five years of leadership and executive management experience, both as an officer in the United States Army and as a financial services executive in Australia. Prior to joining Ecofibre, he served as Captain and Apache pilot in the US Army for eight years in a range of roles, including Troop Commander, Operations Officer, Executive Officer and Personnel Officer in the United States and Europe. He is the Chief Operating Officer at Petpetual Investments. He is also the Chief Operating Officer at Perpetual Limited. Mr. Wang joined Perpetual in 2004 and was appointed Chief Operating Officer in 2007. In this role, he is responsible for Product, Client Service, Operations, Information Technology, and Fund Accounting. Mr. Wang also has responsibility for Perpetual's Platform and Structured Products businesses. Previously, he was the Chief Operating Officer at the Wealth Management Division and the General Manager of Group Strategy. Prior to joining Perpetual, Mr. Wang was a Strategy Consultant at Bain and Company and a Captain in the US Army. Mr. Wang is currently a Director of Perpetual Investment Management Limited, Perpetual Superannuation Limited, and Perpetual Trustee Company Limited. He has a Bachelor of Science from the United States military academy, West Point and an M.B.A. from Dartmouth.

CEO Compensation
  • Insufficient data for Eric to compare compensation growth.
  • Insufficient data for Eric to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team

Eric Wang

TITLE
CEO, MD & Director
TENURE
1.4 yrs

Jonathan Brown

TITLE
CFO & Company Secretary

Adam Cantwell

TITLE
VP of Global Operations

Alastair Bor

TITLE
Chief Technology Officer

Alex Capano

TITLE
Chief Science Officer
Board of Directors Tenure

Average tenure of the Ecofibre board of directors in years:

1.6
Average Tenure
  • The average tenure for the Ecofibre board of directors is less than 3 years, this suggests a new board.
Board of Directors

Barry Lambert

TITLE
Non-Executive Chairman
AGE
71
TENURE
1.6 yrs

Eric Wang

TITLE
CEO, MD & Director
TENURE
3.4 yrs

Jon Meadmore

TITLE
Non-Executive Director
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Ecofibre's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ecofibre has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Ecofibre Limited, together with its subsidiaries, produces and sells hemp products in the United States and Australia. The company offers protein powders, dehulled hemp seeds, hemp oil, tinctures, and gel capsules. It also produces nutraceutical products for human and pet consumption, as well as topical creams and salves; and develops hemp related fiber products. The company was founded in 2009 and is based in Sydney, Australia.

Details
Name: Ecofibre Limited
EOF
Exchange: ASX
Founded: 2009
A$668,194,166
309,349,151
Website: http://www.ecofibre.com
Address: Ecofibre Limited
680 George Street,
Level 12,
Sydney,
New South Wales, 2000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX EOF Ordinary Shares Australian Securities Exchange AU AUD 29. Mar 2019
CHIA EOF Ordinary Shares Chi-X Australia AU AUD 29. Mar 2019
Number of employees
Current staff
Staff numbers
0
Ecofibre employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/22 10:39
End of day share price update: 2019/05/21 00:00
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.